氨苯砜治疗慢性特发性与自身免疫性荨麻疹的应用
该回顾性病历 review 纳入2005年1月1日至2017年4月15日在纽约大学医学院三级学术医疗中心就诊的79例慢性自发性荨麻疹(CSU)患者,评估口服氨苯砜的疗效与安全性;78%患者改善,47%的改善者达完全缓解,16例出现轻度不良反应,2例严重不良反应;作者认为氨苯砜是抗组胺药一线治疗失败后有用且耐受良好的二线治疗。
要点
- 79例CSU患者中78%获改善,其中47%达完全缓解。
- 平均改善时间1.1个月,平均完全缓解时间5.2个月。
- 16例轻度不良反应,2例严重不良反应。
核心结论
- 作者认为氨苯砜是抗组胺药及其他一线药物失败后CSU患者有用且耐受良好的二线治疗。
研究设计与样本
- 回顾性病历 review,纳入2005年1月1日至2017年4月15日在纽约大学医学院三级学术医疗中心就诊的79例口服氨苯砜治疗的CSU患者,随访于2018年2月28日完成。
主要发现
- 79例患者(65%女性;平均[SD]年龄49.8[16.1]岁,范围20-79岁)中45例为慢性特发性荨麻疹,34例为慢性自身免疫性荨麻疹。
- 62例(78%)获改善(特发性36例[80%],自身免疫性26例[76%]),平均[SD]改善时间1.1(1.0)个月。
- 62例改善者中29例(47%)达完全缓解(特发性16例[44%],自身免疫性13例[50%]),平均[SD]完全缓解时间5.2(5.2)个月。
- 21例在平均[SD]2.4(2.2)个月后减量,18例停药;10例获缓解且停药后随访0.3至10.0个月无复发。
- 16例出现轻度不良反应,报告2例严重不良反应。
临床怎么用
- 原文未据此给出推荐;作者认为氨苯砜是抗组胺药及其他一线药物失败后CSU患者有用且耐受良好的二线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The first-line treatment for patients with chronic spontaneous urticaria (CSU), which is divided into idiopathic and autoimmune subtypes, consists of H1-antihistamines. However, limited evidence guides the treatment of CSU after maximal therapy with antihistamines fails. Two randomized clinical trials suggest that dapsone may be a successful second-line therapy. OBJECTIVE: To evaluate the efficacy and safety of dapsone therapy in patients with CSU. DESIGN, SETTING, AND PARTICIPANTS: This retrospective medical record review included 79 patients with CSU treated with dapsone who presented to the tertiary care academic medical center at the New York University School of Medicine, New York, New York, from January 1, 2005, through April 15, 2017. Follow-up was completed on February 28, 2018. Data were analyzed from March 1 through May 31, 2018. EXPOSURES: Treatment with oral dapsone for CSU. MAIN OUTCOMES AND MEASURES: Efficacy of dapsone therapy for CSU was evaluated as improvement, complete response, and remission. RESULTS: Seventy-nine patients (65% women; mean [SD] age, 49.8 [16.1] years [range, 20-79 years]) were included in the analysis. Forty-five patients had chronic idiopathic urticaria and 34 had chronic autoimmune urticaria. Improvement in CSU was observed in 62 patients (78%) (36 [80%] with idiopathic and 26 [76%] with autoimmune disease) with dapsone. Mean (SD) time to improvement was 1.1 (1.0) months. A complete response was achieved in 29 (47%) of these 62 patients (16 [44%] with idiopathic and 13 [50%] with autoimmune disease). Mean (SD) time to complete response was 5.2 (5.2) months. Dapsone therapy was tapered in 21 patients after a mean (SD) of 2.4 (2.2) months and discontinued in 18. Ten patients experienced remission with no subsequent flares, even after dapsone therapy was discontinued with follow-up of 0.3 to 10.0 months. Sixteen patients experienced mild adverse effects. Two serious adverse effects were reported. CONCLUSIONS AND RELEVANCE: Results of this study suggest that dapsone is a useful and well-tolerated second-line therapy for patients with CSU in whom antihistamines and other first-line agents have failed.
引用
- Liang SE, Hoffmann R, Peterson E, et al. Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune Urticaria. JAMA Dermatol. 2019. PMID: 30476976. doi:10.1001/jamadermatol.2018.3715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。